Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Trial Profile

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs Pemafibrate (Primary)
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use
  • Acronyms PROMINENT
  • Sponsors Kowa
  • Most Recent Events

    • 17 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 15 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top